Logo

ConcertAI, Caris Life Sciences, and AbbVie Collaborate to Enhance AbbVie’s Research and Development Efforts Towards Cancer Treatment

Share this
AbbVie

ConcertAI, Caris Life Sciences, and AbbVie Collaborate to Enhance AbbVie’s Research and Development Efforts Towards Cancer Treatment

Shots:

  • ConcertAI & Caris Life Sciences has signed a multi-year agreement with AbbVie to delve into and support AbbVie’s precision medicine-driven research and development & clinical trial optimization for cancer treatment
  • Under the terms of the agreement, AbbVie will receive the rights to use Caris’ expansive real-world, multi-modal database in oncology & ConcertAI’s research-grade clinical data across various cancer indications
  • In addition, AbbVie will be able to improve cancer clinical trials and patient enrolment by deploying AI/ML learning in combination with ConcertAI & Caris' clinical network & laboratory capabilities

Ref: Caris Life Sciences  | Image: AbbVie

Related News:- Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions